Abstract 90P
Background
Immune surveillance is closely related to MHC and its associated molecules. The MHC class I chain related B molecule (MICB) is one of the ligands of NKG2D receptor. NKG2D receptor exists in NK cells and CD8+ T cells, which mediate anti-tumor response and immune surveillance. MICB is expressed by intestinal epithelium and epithelial tumors as well. Cancer cells express MICB as the consequence of cellular stress. But tumor cells might develop evasive pathways to avoid NK cell attack. Shedding is a way for cancer cells to remove or avoid the surface expression of MICB. Previous studies haven’t clearly figured out the prognostic value of MICB in colorectal cancer (CRC). Here, we figured out the relationship between MICB and prognosis in a CRC cohort of Zhongshan Hospital. The prognostic benefit was also validated in GSE39582 from Gene Expression Omnibus repository.
Methods
863 consecutive CRC patients from 2008 to 2012 without prior treatment were enrolled. 556 CRC patients between 1987 to 2007 were collected from GSE39582. MICB was detected by immunochemistry. MICB score equaled MICB intensity multiplied by the percentage of positive cells among all tumor cells. The cut-off value of MICB score was calculated by X-tile. The association between clinicopathological features and MICB were accessed by chi-square test. Kaplan-Meier analysis and log-rank test were performed to evaluate the relationship between MICB and overall survival. Univariate and multivariate cox regression analyses were performed to identify the independent prognostic factors.
Results
High MICB was significantly associated with non-mucinous histological type (p < 0.001) and ≤4.0cm tumor size (p = 0.001). Kaplan-Meier analyses and log-rank test showed high MICB group had a better overall survival (p = 0.002). In cox regression analyses of Zhongshan cohort, MICB was confirmed as an independent prognostic factor of OS (p = 0.008, HR = 0.741, 95% CI = 0.594-0.924).
Conclusions
MICB was identified as a new independent prognostic factor in stage one to stage four CRC patients. CRC with high MICB expression conferred survival benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital, Fudan University, Shanghai, China.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract